Skip to main content
uniQure N.V. logo

uniQure N.V. — Investor Relations & Filings

Ticker · QURE ISIN · NL0010696654 LEI · 724500RPCTZLFYJZ3S98 US Manufacturing
Filings indexed 859 across all filing types
Latest filing 2026-05-05 Quarterly Report
Country NL Netherlands
Listing US QURE

About uniQure N.V.

https://www.uniqure.com/

uniQure N.V. is a gene therapy company focused on developing and commercializing treatments for patients with rare and severe diseases. The company utilizes its adeno-associated virus (AAV) based technology platform to create single-administration therapies with the potential for curative results. Its research and development pipeline is concentrated on liver-directed and central nervous system (CNS) disorders, with a key clinical program targeting Huntington's disease. uniQure aims to deliver transformative medicines by translating scientific innovation into viable treatments.

Recent filings

Filing Released Lang Actions
10-Q - uniQure N.V. (0001590560) (Filer)
Quarterly Report
2026-05-05 English
8-K - uniQure N.V. (0001590560) (Filer)
Regulatory Filings
2026-05-05 English
8-K - uniQure N.V. (0001590560) (Filer)
Regulatory Filings
2026-04-30 English
ARS - uniQure N.V. (0001590560) (Filer)
Annual Report
2026-04-27 English
DEF 14A - uniQure N.V. (0001590560) (Filer)
Proxy Solicitation & Information Statement
2026-04-27 English
4 - UNIQURE N.V. (0001590560) (Filer)
Director's Dealing
2026-03-04 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.